VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
VERACYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$43.80+0.68 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $3.59B
- P/E (TTM)
- 31.3
- Dividend yield
- –
VERACYTE, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Testing revenue | $544.33M | $520.94M | $493.15M | $469.48M | $451.26M | $435.97M | $418.96M | $397.19M | $369.67M | $344.45M | $326.54M | $306.43M | 96.9% | +20.6% |
| Product revenue | $14.69M | $14.43M | $14.33M | $13.50M | $13.39M | $13.69M | $13.65M | $14.30M | $15.13M | $15.23M | $15.59M | $15.15M | 2.6% | +9.7% |
| Other Testing Revenue | $12.70M | $10.00M | $6.20M | $5.50M | $7.10M | $9.30M | $11.80M | $12.40M | $10.20M | $8.50M | $7.80M | – | 2.3% | +78.9% |
| Biopharmaceutical and other revenue | $2.88M | $6.38M | $9.66M | $12.16M | $14.48M | $13.73M | $13.15M | $13.84M | $14.78M | $15.79M | $18.92M | $21.57M | 0.5% | -80.1% |
| Biopharmaceutical revenue | $2.71M | $4.54M | $6.54M | $6.76M | $8.16M | $7.23M | $7.15M | $7.98M | $8.77M | $10.38M | $13.87M | $16.11M | 0.5% | -66.7% |
| Contract manufacturing and testing | – | – | – | $5.40M | $6.33M | $6.51M | $6.00M | $5.86M | $6.01M | $5.41M | $5.05M | $5.46M | – | – |
By region
From the segment and revenue-disaggregation notes of Veracyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.